1 / 24

QTc and Quinolones: recent regulatory actions

QTc and Quinolones: recent regulatory actions. Joyce Korvick M.D., M.P.H. Office of Drug Evaluation IV Division of Special Pathogens FDA. Overview: Quinolone Antibiotics . Background Recent approvals Comparison of Selected Characteristics Considerations & Approach to Regulatory Actions.

fynn
Download Presentation

QTc and Quinolones: recent regulatory actions

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. QTc and Quinolones:recent regulatory actions Joyce Korvick M.D., M.P.H. Office of Drug Evaluation IV Division of Special Pathogens FDA

  2. Overview:Quinolone Antibiotics • Background • Recent approvals • Comparison of Selected Characteristics • Considerations & Approach to Regulatory Actions

  3. Background • Antibiotics- • Short term use (<14 days) • Track record of macrolides • Erythromycin post-marketing experience • Quinolones • Sparfloxacin (approved 1995, low volume use) • Grepafloxacin (approved 1997,low volume use)

  4. Background • Spontaneous withdrawal of Grepafloxacin (Raxar) by Glaxo (11/99) • Original labeling: contraindication • Post-marketing QT experience

  5. Moxifloxacin(Avelox)

  6. Anti-infectives Advisory Committee (10/99) • Moxifloxacin (Avelox) • Pre-clinical data • Phase I/II QT studies • Electrocardiographic studies in Phase III • OPDRA presentation re: post-marketing experience in approved antibiotics

  7. Pre-Clinical Animal Data: Moxifloxacin • Significant changes in animal models with • rapid infusion • extreme dose

  8. All Patients with ECGs

  9. Mean changes of QTcB (QT) in mS for patients with valid paired ECGs

  10. Mean serum concentration after 400mg Moxifloxacin oral dose = 2165 mcg/l SD 588

  11. Mean prolongation of QTc

  12. Summary • Blocked Ikr at 3x concentration of sparfloxacin • prolonged APD at 50M vs 3M for sparfloxacin • Dose related prolongation in animals and humans • Mean prolongation 5mS (oral 400mg) 12mS (IV 400mg) • outliers • increased changes with hypokalemia

  13. Gatifloxacin (Tequin) • Pre-clinical data • Phase I/II QT studies • Electrocardiographic studies in phase III • patients with QT prolonging drugs not excluded

  14. Gatifloxacin

  15. Selected Characteristics

  16. Quinolone Characteristics

  17. Considerations at Approval • Unique characteristics • Spectrum of indications • Metabolic pathways • Potential for drug-drug interactions • Short-term vs. chronic administration • Route of administration

  18. Approach to Regulatory Action • Labeling within drug class • Warning • Information to Patient Section

  19. Gatifloxacin (Tequin ) Label WARNINGS: GATIFLOXACIN MAY HAVE THE POTENTIAL TO PROLONG THE QTc INTERVAL OF THE ELECTROCARDIOGRAM IN SOME PATIENTS. DUE TO THE LACK OF CLINICAL EXPERIENCE, GATIFLOXACIN SHOULD BE AVOIDED IN PATIENTS WITH KNOWN PROLONGATION OF THE QTc INTERVAL, PATIENTS WITH UNCORRECTED HYPOKALEMIA, AND PATIENTS RECEIVING CLASS IA (E.G. QUINIDINE, PROCAINAMIDE) OR CLASS III (E.G. AMIODARONE, SOTALOL) ANTIARRHYTHMIC AGENTS.

  20. Approach to Regulatory Action • Phase IV Commitments • pK/pD: ECG Monitoring • Controlled studies within quinolone/macrolide classes • Dose escalation to at least 2X recommended dose

  21. Approach to Regulatory Action • Phase IV Commitments • Post-Marketing • Adverse Event Surveillance Protocol* • MedWatch • Pharmaceutical Company Reports

  22. ODE IV Continuing Response • Commitment to Anti-infective AC • Assess class labeling approach for all approved • Quinolones • Macrolides • Current Activities • Office level QT working group • Letter to all current NDA holders re: QT data • Coordination within Office: review of NDAs

  23. Patient Information About:TEQUIN 200 mg and 400 mg Tablets • Who should not take TEQUIN? • You should avoid TEQUIN if you have a rare condition known as congenital prolongation of the QTc interval. If any of your family members have this condition, you should inform your health care professional. • You should avoid TEQUIN if you are being treated for heart rhythm disturbances with certain medicines such as quinidine, procainamide, amiodarone, or sotalol. Inform your healthcare professional if you are taking a heart rhythm drug. • TEQUIN should be avoided in patients with a condition known as hypokalemia (low blood potassium). • Hypokalemia may be caused by medicines called diuretics such as furosemide and hydrochlorothiazide. If you are taking a diuretic you should speak with your healthcare professional

  24. Patient Information About:TEQUIN 200 mg and 400 mg Tablets • What are the possible side effects of TEQUIN? • TEQUIN is generally well tolerated. The most common side effects that can occur when taking TEQUIN are usually mild, and include nausea, vomiting, stomach pain, diarrhea, dizziness, and headache. ……. • In a few people, TEQUIN, like some other antibiotics, may produce a small effect on the heart that is seen on an electrocardiogram test. Although this has not caused any problems in more than 4000 patients who have taken TEQUIN in clinical trials, in theory, it could result in extremely rare cases of abnormal heartbeat, that may be dangerous. Contact your healthcare professional if you develop heart palpitations (fast beating), or have fainting spells.

More Related